Quantitative modeling predicts competitive advantages of a next generation anti‐NKG2A monoclonal antibody over monalizumab for the treatment of cancer

A semimechanistic pharmacokinetic (PK)/receptor occupancy (RO) model was constructed to differentiate a next generation anti‐NKG2A monoclonal antibody (KSQ mAb) from monalizumab, an immune checkpoint inhibitor in multiple clinical trials for the treatment of solid tumors. A three‐compartment model i...

Descripción completa

Detalles Bibliográficos
Autores principales: Spinosa, Phillip, Musial‐Siwek, Monika, Presler, Marc, Betts, Alison, Rosentrater, Emily, Villali, Janice, Wille, Lucia, Zhao, Yang, McCaughtry, Tom, Subramanian, Kalyanasundaram, Liu, Hanlan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7965834/
https://www.ncbi.nlm.nih.gov/pubmed/33501768
http://dx.doi.org/10.1002/psp4.12592

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7965834/
https://www.ncbi.nlm.nih.gov/pubmed/33501768
http://dx.doi.org/10.1002/psp4.12592

Ejemplares similares